Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.

Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA.

Neuro Oncol. 2011 Apr;13(4):384-92. doi: 10.1093/neuonc/noq193. Epub 2011 Feb 11.

2.

Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.

Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.

Endocrinology. 2013 Mar;154(3):1247-59. doi: 10.1210/en.2012-1908. Epub 2013 Feb 5.

PMID:
23384836
3.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007. Epub 2015 Jul 15.

PMID:
26188279
4.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

5.

Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.

Yuan Y, Xue X, Guo RB, Sun XL, Hu G.

CNS Neurosci Ther. 2012 Jul;18(7):536-46. doi: 10.1111/j.1755-5949.2012.00319.x. Epub 2012 Apr 25.

PMID:
22530672
6.

Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.

Kohsaka S, Takahashi K, Wang L, Tanino M, Kimura T, Nishihara H, Tanaka S.

Cancer Lett. 2013 Apr 30;331(1):68-75. doi: 10.1016/j.canlet.2012.12.005. Epub 2012 Dec 12.

PMID:
23246370
7.

Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.

Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2012 Aug;11(8):1758-69. doi: 10.1158/1535-7163.MCT-12-0015. Epub 2012 Jul 30.

8.

ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.

Nadkarni A, Shrivastav M, Mladek AC, Schwingler PM, Grogan PT, Chen J, Sarkaria JN.

J Neurooncol. 2012 Dec;110(3):349-57. doi: 10.1007/s11060-012-0979-0. Epub 2012 Oct 3.

9.

Transcriptional targeting of adenovirally delivered tumor necrosis factor alpha by temozolomide in experimental glioblastoma.

Yamini B, Yu X, Gillespie GY, Kufe DW, Weichselbaum RR.

Cancer Res. 2004 Sep 15;64(18):6381-4.

10.

Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.

Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.

Clin Cancer Res. 2014 Jul 15;20(14):3730-41. doi: 10.1158/1078-0432.CCR-13-3446. Epub 2014 May 16.

11.

p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts.

Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD.

Cancer Res. 2008 Dec 15;68(24):10034-9. doi: 10.1158/0008-5472.CAN-08-1687.

12.

Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.

Viel T, Monfared P, Schelhaas S, Fricke IB, Kuhlmann MT, Fraefel C, Jacobs AH.

Mol Ther. 2013 Mar;21(3):570-9. doi: 10.1038/mt.2012.278. Epub 2013 Jan 15.

13.

Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma.

Mirzoeva OK, Hann B, Hom YK, Debnath J, Aftab D, Shokat K, Korn WM.

J Mol Med (Berl). 2011 Sep;89(9):877-89. doi: 10.1007/s00109-011-0774-y. Epub 2011 Jun 16.

PMID:
21678117
14.

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.

PLoS One. 2012;7(10):e44372. doi: 10.1371/journal.pone.0044372. Epub 2012 Oct 2.

15.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

16.

In vitro and in vivo effect of human lactoferrin on glioblastoma growth.

Arcella A, Oliva MA, Staffieri S, Aalberti S, Grillea G, Madonna M, Bartolo M, Pavone L, Giangaspero F, Cantore G, Frati A.

J Neurosurg. 2015 Oct;123(4):1026-35. doi: 10.3171/2014.12.JNS14512. Epub 2015 Jul 17.

PMID:
26186026
17.

Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.

Lee DY, Chunta JL, Park SS, Huang J, Martinez AA, Grills IS, Krueger SA, Wilson GD, Marples B.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):978-85. doi: 10.1016/j.ijrobp.2013.04.034.

PMID:
23845846
18.

Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.

Clin Cancer Res. 2003 Nov 1;9(14):5370-9.

19.

Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.

Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C.

Neuro Oncol. 2010 Dec;12(12):1205-19. doi: 10.1093/neuonc/noq103. Epub 2010 Sep 22.

20.

Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.

Lan F, Pan Q, Yu H, Yue X.

J Neurochem. 2015 Sep;134(5):811-8. doi: 10.1111/jnc.13174. Epub 2015 Jun 11.

PMID:
25991372
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk